PwC's "White Paper on Big Health Industry Investment in the Background of the Belt and One Road" released in Beijing on the 21st shows that overseas investment transactions by Chinese companies in the medical field have increased substantially since 2014, reaching 43.53 in the first half of 2017 In the recent three years, private-owned enterprises dominated the overseas pharmaceutical M & A market, with total transaction volume reaching 21 times that of state-owned enterprises.
Xing Liping, a partner of PricewaterhouseCoopers China Healthcare Industry Consulting Service, said: "In recent years, the hot domestic M & A market has led to a decrease in the number of high-quality labels and a rise in valuation. Domestic companies have turned their attention overseas to seek a reasonable target for the acquisition '
The report shows that domestic enterprises are more inclined to the biopharmaceutical industry and the number and amount of transactions of exporting and acquiring biopharmaceuticals in the past year are obviously higher than those of medical devices.Health industry in developed North America and Europe is the primary investment destination for Chinese enterprises in recent years .
Xing Liping said that domestic enterprises hope to introduce overseas high-quality medical resources and business models into China to speed up the strategic layout of their domestic medical and health businesses and at the same time, they will take the acquisition of the target as a platform to open up overseas markets.
In addition, PricewaterhouseCoopers advised that there are many countries along the Belt and Road, and investors should pay attention to the risks in their geopolitical, economic environment, social culture, labor disputes, taxation and market access.
